Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 26Neuroblastoma 25Breast Neoplasms 20Prostatic Neoplasms 18Leukemia 15Multiple Myeloma 14Lymphoma 14Leukemia, Myeloid, Acute 14Glioblastoma 14Lymphoma, Non-Hodgkin 10Neoplasms 9Ovarian Neoplasms 8Neoplasm Metastasis 8Leukemia, Lymphocytic, Chronic, B-Cell 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms, Male 8Myelodysplastic Syndromes 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Glioma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Fallopian Tube Neoplasms 6Osteosarcoma 5Hodgkin Disease 5Carcinoma, Renal Cell 5Brain Neoplasms 5Uveal Melanoma 4Recurrence 4Rectal Neoplasms 4Medulloblastoma 4

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT05307835 2025-12-02

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Active not recruiting
27 enrolled
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡